v3.26.1
Acquisition of Astria Therapeutics, Inc. - Schedule of Consideration Transferred (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jan. 23, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Business Combination [Line Items]          
Cash consideration       $ 612 $ 322
Assets acquired and liabilities assumed:          
IPR&D - navenibart   $ 0 $ 0 697,761 $ 0
Astria          
Business Combination [Line Items]          
Equity consideration $ 251,655        
Cash consideration 608,633        
Direct transaction costs 14,025        
Total purchase price 874,313        
Assets acquired and liabilities assumed:          
Cash and cash equivalents 130,588        
Short-term investments 63,033        
Trade receivables 1,980        
Prepaid expenses and other current assets 5,547        
Property and equipment 642        
Other assets 14,417        
Right of use asset   4,198        
IPR&D - navenibart 705,267     $ 697,761  
Assembled workforce 600        
Accounts payable (22,627)        
Accrued expenses (10,146)        
Operating lease liabilities, current (1,249)        
Deferred revenue, current (4,598)        
Operating lease liabilities, net of current portion (2,949)        
Deferred revenue, net of current portion (10,390)        
Net assets acquired $ 874,313        
Purchase price, shares issued (shares) 37,282        
Price per share (in usd per share) $ 6.75